Trial · NCT01245673

Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma

NCT01245673, Phase 2, Completed, University of Pennsylvania; results first posted 2020-03-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma. Trials, record NCT01245673. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01245673

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
NCT number: NCT01245673
Status: Completed
Phases: Phase 2
Enrollment: 28 participants, actual
Lead sponsor: University of Pennsylvania
Conditions: Myeloma
Interventions: Prevnar- Pneumococcal Conjugate Vaccine (PCV), Activated/costimulated autologous T-cell, Revlamid® (Lenalidomide), MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)
First posted: 2010-11-22
Last updated: 2020-04-06
Results first posted: 2020-03-19

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Primary Myeloma Endpoint	Between day 100 and 180 post transplant	To determine whether lenalidomide maintenance plus the late booster immunizations leads to improved myeloma clinical responses between day 180 and day 100 post-transplant.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Primary Myeloma Endpoint	Between day 100 and 180 post transplant	Subjects that reached D100 and D180	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Primary Myeloma Endpoint	Prevnar, T Cells, Lenalidomide, MAGE A-3	Subjects in CR D100 and D180	4	Participants
Primary Myeloma Endpoint	Prevnar, T Cells, Lenalidomide, MAGE A-3	Subjects in sCR D100 and 180	1	Participants
Primary Myeloma Endpoint	Prevnar, T Cells, Lenalidomide, MAGE A-3	Subjects in VGPR D100 and D180	1	Participants
Primary Myeloma Endpoint	Prevnar, T Cells, Lenalidomide, MAGE A-3	Subjects in PR D100 and D180	5	Participants
Primary Myeloma Endpoint	Prevnar, T Cells, Lenalidomide, MAGE A-3	Subjects with SD at D+100 and 180	3	Participants
Primary Myeloma Endpoint	Prevnar, T Cells, Lenalidomide, MAGE A-3	Subjects with improved response at D100 and D180	6	Participants
Primary Myeloma Endpoint	Prevnar, T Cells, Lenalidomide, MAGE A-3	Subjects with poorer response at D100 and D180	4	Participants
Primary Myeloma Endpoint	Prevnar, T Cells, Lenalidomide, MAGE A-3	Subjects with no disease response reported	2	Participants

Source ClinicalTrials.gov

Participant flow19

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Enrollment	STARTED	MAGE A-3, GM-CSF, Hiltonol®, T Cells, Lenalidomide,	28
Enrollment	COMPLETED	MAGE A-3, GM-CSF, Hiltonol®, T Cells, Lenalidomide,	27
Enrollment	NOT COMPLETED	MAGE A-3, GM-CSF, Hiltonol®, T Cells, Lenalidomide,	1
Pre Transplant Vaccinations	STARTED	MAGE A-3, GM-CSF, Hiltonol®, T Cells, Lenalidomide,	27
Pre Transplant Vaccinations	Pre Transplant Vaccinations 1-3	MAGE A-3, GM-CSF, Hiltonol®, T Cells, Lenalidomide,	27
Pre Transplant Vaccinations	COMPLETED	MAGE A-3, GM-CSF, Hiltonol®, T Cells, Lenalidomide,	27
Pre Transplant Vaccinations	NOT COMPLETED	MAGE A-3, GM-CSF, Hiltonol®, T Cells, Lenalidomide,	0
Activated/Costimulated Autologous T Cell	STARTED	MAGE A-3, GM-CSF, Hiltonol®, T Cells, Lenalidomide,	27
Activated/Costimulated Autologous T Cell	COMPLETED	MAGE A-3, GM-CSF, Hiltonol®, T Cells, Lenalidomide,	27
Activated/Costimulated Autologous T Cell	NOT COMPLETED	MAGE A-3, GM-CSF, Hiltonol®, T Cells, Lenalidomide,	0

1 to 10 of 19Source ClinicalTrials.gov

See all 19 participant flow

Adverse events46

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anorexia	Metabolism and nutrition disorders	Prevnar, T Cells, Lenalidomide, MAGE A-3	9	27	14
other	Chills	General disorders	Prevnar, T Cells, Lenalidomide, MAGE A-3	5	27	7
other	Diarrhea	Gastrointestinal disorders	Prevnar, T Cells, Lenalidomide, MAGE A-3	4	27	5
other	Fatigue	General disorders	Prevnar, T Cells, Lenalidomide, MAGE A-3	7	27	7
other	Fever	General disorders	Prevnar, T Cells, Lenalidomide, MAGE A-3	10	27	16
other	Flu-like symptoms	Infections and infestations	Prevnar, T Cells, Lenalidomide, MAGE A-3	2	27	3
other	Generalized muscle weakness	Musculoskeletal and connective tissue disorders	Prevnar, T Cells, Lenalidomide, MAGE A-3	2	27	2
other	Headache	Nervous system disorders	Prevnar, T Cells, Lenalidomide, MAGE A-3	8	27	10
other	Increased eosinophil	Blood and lymphatic system disorders	Prevnar, T Cells, Lenalidomide, MAGE A-3	2	27	3
other	Induration	Skin and subcutaneous tissue disorders	Prevnar, T Cells, Lenalidomide, MAGE A-3	3	27	5

1 to 10 of 46Source ClinicalTrials.gov

See all 46 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Prevnar, T Cells, Lenalidomide, MAGE A-3	0	27
Total, other adverse events	Prevnar, T Cells, Lenalidomide, MAGE A-3	27	27
Total, serious adverse events	Prevnar, T Cells, Lenalidomide, MAGE A-3	9	27

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
24520093	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01245673

GET https://conductscience.org/api/trials/v1/NCT01245673/events?page=2

API reference For AI assistants